《复牌公告》罗马集团(08072.HK)拟折让31.3%一供三筹最少6,290万元
罗马集团(08072.HK)公布,建议按每持有1股现有股份获发3股供股股份之基准进行供股,认购价每股0.125元,较股份停牌前股价0.182元折让31.3%。发行股份介乎5.27亿股至5.55亿股,占公司扩大後股本75%。
公司预期,是次供股集资净额介乎6,290万元至6,640万元,其中最少4,200万元将用作增加营运资金供经营及扩展现有业务,最少1,540万元将用作偿还债务,另外最多550万元将用作潜在收购及投资。
公司并建议更改每手买卖单位,自每手1万股改为每手2万股。今早起复牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.